STOCK TITAN

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Chairman and CEO, Michael S. Weiss, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference on November 6-7, 2023. The fireside chat with Weiss is scheduled for November 6 at 3:10 PM ET and will be webcasted live on the Company's website.
Positive
  • None.
Negative
  • None.

Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023. The fireside chat is scheduled to take place on Monday, November 6, 2023, at 3:10 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as European Commission (EC) approval for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com 
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com 
Telephone: 1.877.575.TGTX (8489), Option 6


FAQ

When is the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference?

The conference will be held on November 6-7, 2023.

Who will participate in the fireside chat?

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, Inc., will participate in the fireside chat.

Where will the conference take place?

The conference will be held at the JW Marriott Essex House in New York City.

What is the schedule for the fireside chat?

The fireside chat is scheduled for Monday, November 6, 2023, at 3:10 PM ET.

How can I watch the fireside chat?

A live webcast of the fireside chat will be available on the Events page of TG Therapeutics' website.

TG Therapeutics, Inc.

NASDAQ:TGTX

TGTX Rankings

TGTX Latest News

TGTX Stock Data

4.98B
140.87M
9.5%
66.38%
18.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK